Francisella tularensis

From IDWiki
Francisella tularensis /
Revision as of 08:56, 3 September 2020 by Aidan (talk | contribs)
  • Zoonontic infection carried on rodents and rabbits and transmitted by biting insects
  • Presentation depends on route of entry: (ulcero)glandular, oculoglandular, pharyngeal, typhoidal, or pneumonic
  • Treatment is streptomycin

Background

Microbiology

  • A fastidious Gram-negative coccobacillus
  • Multiple subspecies, including tularensis, holarctica, novocida, mediasiatica, which are further subdivided into clades, and related species Francisella philomiragia and Francisella hispaniensis
  • Subspecies of importance to humans include:
    • Subspecies tularensis (type A strains)
      • Found in North America and rarely Europe
      • Two major clades (AI and AII) and four subclades (AIa, AIb, AIIa, and AIIb)
      • Overall the subspecies is the most virulent subspecies, and specifically the AIb subclade is the most virulent strain
    • Subspecies holarctica (type B strains)
      • Found in the entire northern hemisphere as well as Australia
      • Four major clades (B4 in North America, B6 in Western Europe, B12 in Eastern Europe and Central Asia, and B16 in Japan and other areas in Eastern Asia) and a number of subclades
    • Subspecies novicida
      • Rare cause of disease in humans, usually in immunocompromised hosts, and presents with bacteremia rather than tularemia
    • Subspecies mediasiatica does not cause disease in humans

History

  • Discovered in 1911 in Tulare county, California
  • Many names: deer fly fever, rabbit fever, etc...

Epidemiology

  • Zoonotic infection whose main animal reservoirs are rodents and rabbits
    • In North America, the most important reservoirs are Sylvilagus species (especially Sylvilagus nuttalii, the cottontail rabbit) and Lepus species lagomorphs (rabbits), and a number of rodents including voles, squirrels, muskrats, and beavers
    • In Europe, the reservoirs include voles, hamsters, mice, and hares
  • Essentially worldwide Northern Hemisphere distribution, especially in the US, Japan, Russia, and Scandinavian countries
  • Transmission:

Pathophysiology

  • Infectious dose depends on route, but is as low as 10 to 50 organisms when injected intradermally or inhaled (or several orders of magnitude higher if ingested)
  • TLR4 has less affinity for its LPS compared to other bacteria
  • Capsule inhibits IgM and complement C3
    • Capsule-deficient strains are both less immunogenic and less virulent
  • Facultative intracellular growth
    • Can infect and persist within erythrocytes, providing protection against aminoglycosides

Clinical Manifestations

  • Incubation period of 3 to 5 days (range 1 to 21 days)
  • The first symptom is usually a papule at the site of inoculation that develops into an ulcer over 1 to 2 days, but this may go unnoticed
  • This is followed by fever which likely corresponds to initial lymphohematogenous dissemination
    • Other common symptoms include chills, headache, malaise, anorexia, and fatigue
    • May also have cough, myalgias, chest discomfort, vomiting, sore throat, abdominal pain, and diarrhea
    • May have a relative bradycardia (more common in US than Europe)
  • These symptoms may remit and relapse, presenting as a subacute relapsing fever over weeks, with associated weight loss, deconditioning, and lymphadenopathy
  • Ulceroglandular: ulcer develops at site of inoculation with tender lymphadenopathy and systemic symptoms
  • Glandular: ulcer is undetectable or healed, only lymphadenopathy and systemic illness remains
  • Oculoglandular: entry through the conjuctiva
  • Pharyngeal: entry through the oropharynx, with exudative pharyngitis/tonsillitis
  • Typhoidal: febrile illness without lymphadenopathy or ulcer, sometimes with diarrhea; patient often has an underlying chronic disease
  • Pneumonic: direct inhalation, often from sheep shearing, landscaping, and microbiology laboratory work

Diagnosis

  • Culture
    • Grows slowly on standard culture media, needs cystine-rich media (e.g. chocolate agar, BHI, or cystine media)
    • Looks bacillary in logarithmic growth phase (small Gram-negative rod), slow-growing only on chocolate agar
  • Serology (EIA) can be used in the right context
  • PCR

Management

  • For severe disease, streptomycin 10 mg/kg (max 1 g) IM q12h for 7 to 10 days
  • For mild to moderate disease, alternatives include:
  • For meningitis, use an aminoglycoside (as above) plus either IV ciprofloxacin, doxycycline, or chloramphenicol for 14 to 21 days
    • Aminoglycosides have poor CNS penetration

Prevention

Vaccination

  • Live attenuated vaccine derived from holarctica

Lab Safety

  • This is a biosafety risk group 3 organism
  • Should be suspected with any slowly-growing, small, and poorly-staining Gram-negative coccobacillus is isolated on chocolate agar but not blood agar
  • Automated laboratory identification systems should not be used, because the risk of aerosol generation
  • Commonly misidentified by automated methods as Haemophilus or Aggregatibacter species